EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (scientific article)

cites work (P2860)

Q33604554	"It's so hard taking pills when you don't know what they're for": a qualitative study of patients' medicine taking behaviours and conceptualisation of medicines in the context of rheumatoid arthritis
Q92931968	"Living a normal life": a qualitative study of patients' views of medication withdrawal in rheumatoid arthritis
Q41185260	"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis
Q38777227	"Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements
Q40035636	'The lesser of two evils…' - views of persons with rheumatoid arthritis on medication adherence: a qualitative study.
Q40770857	(18)F-FDG and (18)F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis
Q34493588	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.
Q28081356	2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative
Q48089791	2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Q47715028	52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
Q51733704	A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference.
Q92885603	A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
Q57323555	A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence
Q50960074	A Humanized Anti-Interleukin 6 Receptor Monoclonal Antibody, Tocilizumab, for the Treatment of Endometriosis in a Rat Model.
Q39088676	A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
Q36205494	A Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study
Q28551075	A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients
Q37337352	A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
Q98770781	A Review of Clinical Applications and Side Effects of Methotrexate in Ophthalmology
Q43926604	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia
Q41132142	A case of rheumatoid arthritis with methotrexate related lymphoproliferative diseases of the knee
Q37203531	A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study
Q40338512	A general practice perspective on early rheumatoid arthritis management: A qualitative study from Flanders
Q50583345	A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis.
Q51103736	A novel electromechanical autoinjector, AutoTouch™, for self-injection of etanercept: real-world use and benefits.
Q92993790	A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients
Q38628540	A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study
Q35843240	A nurse-led rheumatology clinic versus rheumatologist-led clinic in monitoring of patients with chronic inflammatory arthritis undergoing biological therapy: a cost comparison study in a randomised controlled trial.
Q27309258	A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis
Q35914971	A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA).
Q37604531	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
Q50546879	A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
Q87785825	A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis
Q47367453	A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
Q33881234	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.
Q26770099	A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective
Q92714001	A systematic review of the factors associated with the initiation of biologicals in patients with rheumatological conditions
Q35762912	APLAR rheumatoid arthritis treatment recommendations.
Q88348165	Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly
Q60920131	Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study
Q92857546	Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register
Q35974381	Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Q39368606	Abatacept: A Review in Rheumatoid Arthritis
Q93026442	Abatacept: from a budget impact model to cost-effectiveness analysis - data from RCT and real life
Q36382309	Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice
Q48076353	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective
Q26799304	Access to an optimal treatment. Current situation
Q38970157	Achievement of NICE quality standards for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis
Q42121483	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
Q48026722	Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy.
Q55265513	Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice.
Q48744497	Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study
Q57817317	Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
Q33740641	Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
Q38539981	Advances in the management of rheumatoid arthritis
Q27001017	Advances in the treatment of polyarticular juvenile idiopathic arthritis
Q38431512	Advances in use of immunomodulatory agents--a rheumatology perspective
Q38928600	Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.
Q38833974	An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions
Q92737146	An audit of the use of hydroxychloroquine in rheumatology clinics
Q39967995	An effective medical partnership in Nagasaki, Japan for patients with rheumatoid arthritis
Q36942901	Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace
Q38591275	Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product
Q38525320	Analysis of patents on anti-rheumatoid arthritis therapies issued in China
Q92188732	Analysis of the Indirect Costs of Rheumatoid Arthritis in Romania
Q42378890	Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium
Q47875926	Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis: a magnetic resonance imaging study
Q36107157	Anti-Carbamylated Protein Antibodies as a Reproducible Independent Type of Rheumatoid Arthritis Autoantibodies
Q38344282	Anti-TNF in rheumatoid arthritis: an overview
Q48282151	Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain.
Q33688001	Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.
Q38946557	Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.
Q33806574	Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis.
Q90726012	Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation
Q54977224	Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Q89099159	Are We Able to Suppress Disease Activity Adequately in Patients With Established Rheumatoid Arthritis? An Observational and Cross-Sectional Study
Q36397598	Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study
Q51741238	Are glucocorticoids harmful to bone in early rheumatoid arthritis?
Q40509594	Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial.
Q55100474	Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania.
Q91695792	Arthritis sensory and motor scale: predicting functional deficits from the clinical score in collagen-induced arthritis
Q41487117	Assessment of Substantial Liver Fibrosis by Real-time Shear Wave Elastography in Methotrexate-Treated Patients With Rheumatoid Arthritis
Q62489203	Assessment of a Deep Learning Model Based on Electronic Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis
Q37587400	Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study
Q47782073	Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 Patients
Q51303242	Asymptomatic colitis induced by low-dose methotrexate.
Q35827953	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in meth
Q89927588	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
Q37639837	Attenuation of Collagen-Induced Arthritis in rat by nicotinic alpha7 receptor partial agonist GTS-21.
Q53455480	Autophagy protects meniscal cells from glucocorticoids-induced apoptosis via inositol trisphosphate receptor signaling.
Q38569860	B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.
Q38761997	Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis.
Q55251974	Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
Q37696609	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Q38922606	Baseline MRI bone erosion predicts the subsequent radiographic progression in early rheumatoid arthritis patients who achieved sustained good clinical response.
Q38837769	Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster
Q88716070	Beyond disease activity to overall disease severity in inflammatory bowel disease
Q51708772	Beyond methotrexate monotherapy for early rheumatoid arthritis.
Q88204290	Biologic agents in inflammatory arthritis
Q26783657	Biologic efficacy optimization--a step towards personalized medicine
Q89838724	Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Q38510023	Biologic monotherapy in the treatment of rheumatoid arthritis
Q36195284	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Q30234528	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Q30235341	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Q24185797	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis
Q38760042	Biosimilar DMARDs: What Does the Future Hold?
Q92480548	Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?
Q55105693	Biosimilars Have Arrived: Rituximab.
Q38591281	Biosimilars for the management of rheumatoid arthritis: economic considerations
Q26744773	Biosimilars in rheumatology: understanding the rigor of their development
Q36215828	Biosimilars: what do patients need to consider?
Q38255765	Blockade of co-stimulation in chronic inflammatory diseases
Q51013068	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).
Q91900949	Bone Marrow Mesenchymal Stem Cells Decrease the Expression of RANKL in Collagen-Induced Arthritis Rats via Reducing the Levels of IL-22
Q39824928	Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
Q58204609	Brief Report: Leucine-Rich α2-Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis
Q92737108	Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs
Q35659545	CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis
Q91045476	CP-25 reverses prostaglandin E4 receptor desensitization-induced fibroblast-like synoviocyte dysfunction via the G protein-coupled receptor kinase 2 in autoimmune arthritis
Q38676104	CT-P13 in the treatment of rheumatoid arthritis.
Q38672568	CTLA-4 blockade in the treatment of rheumatoid arthritis: an update
Q48152945	CTLA-4 expressed by FOXP3+ regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis.
Q38725092	Calcium channels: the potential therapeutic targets for inflammatory bone destruction of rheumatoid arthritis
Q39164961	Can Rheumatologists Predict Eventual Need for Orthopaedic Intervention in Patients with Rheumatoid Arthritis? Results of a Systematic Review and Analysis of Two UK Inception Cohorts
Q48519138	Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?
Q38598776	Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?
Q34573121	Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study
Q40660533	Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom
Q46394309	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
Q34520662	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis
Q30240180	Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
Q37425952	Cartilage damage and bone erosion are more prominent determinants of functional impairment in longstanding experimental arthritis than synovial inflammation.
Q38972531	Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases
Q24193535	Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Q47836056	Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Q35351313	Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
Q38198118	Certolizumab pegol in rheumatoid arthritis: current update
Q36045392	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Q57245381	Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry?
Q26800716	Challenges faced in Latin America for the implementation of an ideal health-care model for rheumatoid arthritis patients: are we ready?
Q36942975	Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
Q38401295	Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort
Q38662688	Characteristics of functional impairment in patients with long-standing rheumatoid arthritis based on range of motion of joints: Baseline data from a multicenter prospective observational cohort study to evaluate the effectiveness of joint surgery i
Q40199980	Characteristics of rheumatoid arthritis patients undergoing reverse shoulder arthroplasty
Q37627829	Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation.
Q48148502	Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.
Q28079074	Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review
Q27006737	Circadian rhythms in rheumatology--a glucocorticoid perspective
Q92837805	Circulating lnc-ITSN1-2 expression presents a high value in diagnosis of rheumatoid arthritis and correlates with disease activity
Q47562955	Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and vali
Q50171622	Clinical Outcome and Long-term Remission in JIA.
Q49527931	Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models
Q34818996	Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
Q26766028	Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
Q40353155	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
Q52624368	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment.
Q38760596	Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey
Q50010475	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.
Q44807577	Clinical guidelines: Addressing comorbidities in systemic inflammatory disorders
Q38364465	Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety
Q36819270	Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
Q55166388	Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study.
Q51226661	Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
Q26753120	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
Q36832755	Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis
Q37715956	Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
Q53093606	Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.
Q38387724	Clocking in: chronobiology in rheumatoid arthritis
Q34415605	Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application
Q61808137	Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach
Q38615462	Co-morbidity index in rheumatoid arthritis: time to think
Q41481648	Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow
Q40924024	Combination Therapy With and Without Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Trials
Q90641416	Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis
Q38270917	Combination therapy for early rheumatoid arthritis: a treatment holiday perspective
Q28066250	Combination therapy with biologic agents in rheumatic diseases: current and future prospects
Q38815347	Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points
Q49788530	Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study
Q30956564	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt
Q37385700	Comparative analysis of educational needs of patients with rheumatic diseases selected based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT).
Q38210539	Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
Q42734907	Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System
Q35242819	Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis
Q57330054	Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis
Q39885959	Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study
Q33778719	Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.
Q51113975	Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis.
Q33572767	Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States
Q47731175	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
Q62111135	Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment
Q37398907	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
Q41471646	Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
Q38990549	Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis.
Q47856769	Comparison of the effectiveness on intra-articular and subcutaneous TNF inhibitor in rheumatoid arthritis patients
Q53179392	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
Q35789299	Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study).
Q36374666	Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?
Q57741148	Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis
Q90582460	Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis
Q28468549	Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats
Q37487299	Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors.
Q97873762	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial
Q36164886	Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study
Q89149086	Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials
Q52587105	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study.
Q88829275	Correlation between hand bone mineral density and joint destruction in established rheumatoid arthritis
Q39066165	Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis.
Q30251996	Correlations between fatigue and disease duration, disease activity, and pain in patients with rheumatoid arthritis: a systematic review.
Q33841358	Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Q40337291	Cost-Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid Arthritis.
Q41601731	Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies
Q39646869	Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study
Q48278236	Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.
Q38775622	Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece
Q33691553	Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis
Q35731438	Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Q36942985	Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis.
Q64250024	Current advances in the treatment of giant cell arteritis: the role of biologics
Q35770303	Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management
Q36125286	Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis
Q38710775	Cyclocurcumin, a curcumin derivative, exhibits immune-modulating ability and is a potential compound for the treatment of rheumatoid arthritis as predicted by the MM-PBSA method
Q88911074	Cystathionine-γ-lyase ameliorates the histone demethylase JMJD3-mediated autoimmune response in rheumatoid arthritis
Q35895890	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database
Q37627351	DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
Q38401848	Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?
Q38607989	Decreased ex vivo production of interferon-gamma is associated with severity and poor prognosis in patients with lupus
Q36603266	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study
Q47336584	Defining and characterizing sustained remission in patients with rheumatoid arthritis
Q38757421	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
Q90102556	Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders
Q35803646	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
Q54222708	Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
Q38559584	Delivering a one-stop, integrated, and patient-centered service for patients with rheumatic diseases
Q35765958	Depression in Rheumatoid Arthritis and its relation to disease activity
Q52381694	Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach.
Q35961312	Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach
Q36087222	Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.
Q90329265	Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments
Q36166791	Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making
Q30847028	Development of a web-based patient decision aid for initiating disease modifying anti-rheumatic drugs using user-centred design methods
Q36278380	Development of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis
Q38937877	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures
Q51387224	Developments with investigational Janus kinase inhibitors for rheumatoid arthritis.
Q41200262	Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid Arthritis
Q38540408	Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations
Q35135754	Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry
Q90457374	Diagnostic value of salivary CRP and IL-6 in patients undergoing anti-TNF-alpha therapy for rheumatic disease
Q50589517	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
Q40095024	Differential influences of Fc gamma receptor blocking on the effects of certolizumab pegol and infliximab on human monocytes
Q35060142	Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice
Q90324208	Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis
Q30874158	Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry
Q36302246	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
Q39902282	Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy
Q30009098	Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases
Q55310713	Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.
Q38988523	Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod
Q26776026	Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis
Q40591907	Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study
Q38698132	Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature
Q39463616	Disparities in care by insurance status for individuals with rheumatoid arthritis: analysis of the medical expenditure panel survey, 2006-2009.
Q36830635	Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs
Q39834837	Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES
Q42021846	Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
Q39192146	Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).
Q47104739	Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial
Q36267592	Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?
Q64063115	Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care
Q47687442	Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
Q39198863	Dosing down with biologic therapies: a systematic review and clinicians' perspective
Q37208456	Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry
Q42683547	Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review
Q37593506	Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis
Q52653996	Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Q38664981	Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Q38648469	Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
Q64062693	Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study
Q53366166	Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
Q36274355	Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis
Q54967304	Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis.
Q53761469	EXXELERATE: a negative trial with importance for clinical practice.
Q58204670	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies
Q50799528	Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Q39027986	Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.
Q40749335	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists
Q38845478	Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
Q26800141	Education for patients with rheumatoid arthritis in Latin America and the Caribbean
Q47862098	Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries.
Q92115742	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Q27335031	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).
Q36211891	Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis.
Q30235141	Effect of methotrexate on bone and wound healing
Q40735887	Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry
Q35977834	Effectiveness of a telemonitoring intensive strategy in early rheumatoid arthritis: comparison with the conventional management approach.
Q30940329	Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry
Q51557013	Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab.
Q37085666	Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Q40729384	Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia
Q53549068	Effectiveness of whole-body magnetic resonance imaging for the efficacy of biologic anti-rheumatic drugs in patients with rheumatoid arthritis: A retrospective pilot study.
Q30984829	Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data
Q52715515	Effects of Artesunate on chondrocyte proliferation, apoptosis and autophagy through the PI3K/AKT/mTOR signaling pathway in rat models with rheumatoid arthritis.
Q41127155	Effects of Concomitant Methotrexate on Large Joint Replacement in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors: A Multicenter Retrospective Cohort Study in Japan
Q92615892	Effects of Conventional and Biological Drugs Used for the Treatment of Rheumatoid Arthritis on the Quality of Life and Depression
Q92539059	Effects of Methotrexate Alone or Combined With Arthritis-Related Biotherapies in an in vitro Co-culture Model With Immune Cells and Synoviocytes
Q38323310	Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis
Q36968754	Effects of needs-based patient education on self-efficacy and health outcomes in people with rheumatoid arthritis: a multicentre, single blind, randomised controlled trial
Q33882788	Effects of polysaccharide fractions isolated from Caltha palustris L. on the activity of phagocytic cells & humoral immune response in mice with collagen-induced arthritis: A comparison with methotrexate
Q47753016	Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time: response data from the tREACH study
Q38745362	Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis
Q36246592	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
Q59791123	Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
Q38203622	Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis
Q39662554	Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs
Q35605449	Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
Q47602038	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials
Q38637585	Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis
Q53789625	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial.
Q34568533	Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)
Q24658506	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Q50044869	Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
Q34047746	Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis
Q53656574	Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis.
Q48089528	Efficacy of abatacept in patients with rheumatoid arthritis, as assessed by magnetic resonance imaging of bilateral hands.
Q36036975	Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis
Q47879980	Efficacy of golimumab for preventing large joint destruction in patients with rheumatoid arthritis as determined by the ARASHI score
Q53918041	Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study.
Q52839293	Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.
Q37562464	Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Q28078943	Emerging Therapies for Rheumatoid Arthritis
Q38633099	Etanercept (Enbrel®) alternative storage at ambient temperature
Q38907998	Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases
Q38653307	Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study
Q37337186	Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis
Q38230740	Etanercept: a review of its use in autoimmune inflammatory diseases
Q40664154	Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation
Q36001911	Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs).
Q41918950	Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts
Q54980743	Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
Q37377948	Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs.
Q53441582	Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept.
Q38711889	Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis
Q40167433	Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis
Q40220296	Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis
Q34587397	Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT.
Q37397943	Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach
Q89997443	Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study
Q50041210	Experience and context shape patient and clinician goals for treatment of rheumatoid arthritis: a qualitative study.
Q38262504	Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians
Q36882847	Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study
Q36133726	Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis
Q89890463	Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
Q38937827	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor
Q33431836	Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases
Q37404912	Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis
Q42375845	Factors associated with the risk of gingival disease in patients with rheumatoid arthritis
Q34354935	Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study
Q31153194	Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
Q39246815	Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis.
Q57483996	Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice
Q37587403	Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study
Q34374946	Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis
Q40710011	Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy
Q36225180	Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate.
Q37345390	Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis
Q37303008	Frequency and trends of disease-modifying antirheumatic drug (DMARD) use in Germany
Q42368157	Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.
Q93147930	Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy
Q48064243	Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials.
Q38936379	Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway
Q36410232	Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis
Q52341767	Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy.
Q33906679	Gist and verbatim communication concerning medication risks/benefits
Q38388487	Glucocorticoid safety for treating rheumatoid arthritis
Q38214242	Glucocorticoid treatment in rheumatoid arthritis
Q34548430	Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis
Q26752725	Glucocorticoids and chronotherapy in rheumatoid arthritis
Q36246088	Glucocorticoids: bad or safe for the bones?
Q41523077	Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.
Q41517903	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study
Q55424021	Golimumab: A Novel Anti-Tumor Necrosis Factor.
Q38771878	Golimumab: A Review in Inflammatory Arthritis
Q47122664	Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis.
Q52382794	Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register.
Q36334999	Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assesso
Q39173670	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
Q35258244	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
Q37116737	High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial
Q38719851	High titer of anti-citrullinated peptide antibody is a risk factor for severe carotid atherosclerotic plaque in patients with rheumatoid arthritis: the TOMORROW study
Q30890060	High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort.
Q92390057	How Do Glucocorticoids Used in Rheumatic Disease Affect Body Weight? A Narrative Review of the Evidence
Q37602033	IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide
Q37111423	Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study
Q33921579	Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy
Q36968011	Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis
Q36183760	Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment
Q38631840	IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis.
Q40385306	Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects
Q90913052	Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology
Q47380976	Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment
Q38473460	Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate
Q38744431	Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23.
Q47614624	Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Q46957950	Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry
Q36005210	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA).
Q38663457	Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis
Q35102134	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
Q45975049	Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
Q40588909	Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial
Q26772850	Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies
Q48165654	Impact of ultrasonography on treatment decision in rheumatoid arthritis: the IMPULSAR study
Q38611683	Implementation of Treat to Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data from the TRACTION Trial
Q38802166	Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial
Q34553844	Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study
Q37531008	Improved survival in rheumatoid arthritis: a general population-based cohort study
Q28071252	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools
Q36243390	Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs
Q64100827	In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis
Q46337002	Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis
Q51070134	Incidence and risk factors for cervical lesions in patients with rheumatoid arthritis under the current pharmacologic treatment paradigm.
Q31137082	Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources
Q30860792	Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis
Q36254129	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study
Q40608716	Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients.
Q28551216	Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
Q45877225	Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change.
Q92068746	Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov-Smirnov Algorithm
Q37236822	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
Q56334428	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
Q36106803	Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis
Q38960108	Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases
Q30240229	Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.
Q41583081	Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists
Q48018323	Inhibitory effect of JAK inhibitor on mechanical stress-induced protease expression by human articular chondrocytes
Q36668191	Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry
Q90049984	Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
Q39000317	Integrating patients' perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan.
Q40105940	Interleukin (IL-6) Immunotherapy
Q55077160	Interleukin-6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors.
Q34047753	Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications
Q34264322	Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol.
Q46360730	Intra-articular methotrexate versus corticosteroid injections in medium-sized joints of rheumatoid arthritis patients-an intervention study
Q91799625	Intracranial Methotrexate-Associated Lymphoproliferative Disorder in Rheumatoid Arthritis
Q37360516	Involvement of P2X7 receptor signaling on regulating the differentiation of Th17 cells and type II collagen-induced arthritis in mice
Q35595158	Is the state of health of rheumatoid arthritis patients receiving adequate treatment, predictable? - Results of a survey.
Q51189427	Isoegomaketone Alleviates the Development of Collagen Antibody-Induced Arthritis in Male Balb/c Mice.
Q36525816	Japanese physicians' preferences for decision making in rheumatoid arthritis treatment
Q51725094	KIR2DL2 and KIR2DS2 as genetic markers to the methotrexate response in rheumatoid arthritis patients.
Q38569688	Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.
Q39330126	Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis.
Q38862981	Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story
Q39890573	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD.
Q64985556	Lessons Learned From the RACAT Trial: A Comparison of Rheumatoid Arthritis Therapies.
Q39162400	Living with persistent rheumatoid arthritis: a BARFOT study
Q38608695	Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Q33725553	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
Q54109855	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.
Q48517263	Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice
Q48599341	Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort
Q36038873	Long-term outcomes of destructive seronegative (rheumatoid) arthritis - description of four clinical cases
Q59800529	Long-term prognosis and quality of life in patients with early rheumatoid arthritis treated according to the 2015 ACR guideline (LELAND): protocol for a multicentre prospective observational study in Southern China
Q40253228	Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients
Q37643408	Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis.
Q38958301	Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study
Q38686396	Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer
Q38652100	Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective
Q41454498	Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III,
Q51273063	Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors.
Q35135825	Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
Q38375821	Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
Q53527795	Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) - A prospective, multicenter, single arm pilot clinical trial.
Q37632332	Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability
Q26781712	Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis
Q38308454	Management of juvenile idiopathic arthritis: hitting the target
Q26786213	Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis
Q35618458	Management of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerations
Q38847005	Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?
Q39646028	Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches
Q33611369	Managing the drug treatment of rheumatoid arthritis.
Q37433305	Measuring transaminases in patients with rheumatoid arthritis on weekly methotrexate: does timing of blood testing matter?
Q89603158	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
Q48610087	Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analy
Q64068261	Medication Adherence and Coping Strategies in Patients with Rheumatoid Arthritis: A Cross-Sectional Study
Q90257324	Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review
Q39043284	Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients
Q26769021	Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration
Q41687198	Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis
Q30251564	Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review
Q24194047	Methotrexate for treating rheumatoid arthritis
Q50133563	Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins.
Q44640038	Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial
Q38214382	Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment
Q36633607	Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B.
Q38939820	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.
Q26751187	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis
Q38272682	Methotrexate revisited: considerations for subcutaneous administration in RA.
Q28085725	Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials
Q99605160	Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naïve Rheumatoid Arthritis Patients
Q40634407	MiR-19 suppresses fibroblast-like synoviocytes cytokine release by targeting toll like receptor 2 in rheumatoid arthritis
Q33849824	MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis
Q95654065	Microbes, helminths, and rheumatic diseases
Q90644532	Mixed methods study of a new model of care for chronic disease: co-design and sustainable implementation of group consultations into clinical practice
Q47108715	Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
Q48308251	Monitoring total-body inflammation and damage in joints and entheses: the first follow-up study of whole-body magnetic resonance imaging in rheumatoid arthritis.
Q28078423	Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
Q26824970	Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
Q38828876	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Q35770656	Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study.
Q41714062	Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis
Q38178003	Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity
Q90718625	Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis
Q92135848	New Therapeutic Targets in Autoimmune Cholangiopathies
Q38220679	New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis
Q27023946	New insights into the impact of neuro-inflammation in rheumatoid arthritis
Q36300250	No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis
Q36141017	Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease
Q58708624	Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment
Q38633143	Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients
Q37587409	Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis
Q38935035	Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission
Q38229893	Novel treatments with small molecules in psoriatic arthritis
Q37021279	Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making
Q48302611	Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up
Q36257543	Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment
Q51474223	Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
Q38434311	Optimizing treatment in paediatric rheumatology--lessons from oncology
Q26778887	Organizing Pneumonia in Rheumatoid Arthritis Patients: A Case-Based Review
Q35899487	Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort
Q35954700	Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis.
Q41156699	Overall conceptual framework for studying the genetics of autoimmune diseases following vaccination: a regulatory perspective
Q56332027	PROMs and Patient Education
Q48273101	Pain relieving and protective effects of Astragalus hydroalcoholic extract in rat arthritis models
Q37453045	Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe
Q92440877	Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA
Q36868373	Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis
Q38663329	Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
Q28071844	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature
Q34316540	Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
Q36145205	Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis.
Q38802434	Patient-Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis
Q40401248	Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort
Q26778271	Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis
Q37728501	Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
Q39230189	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
Q55397612	Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature.
Q58557964	Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
Q35577166	Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
Q38887484	Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain
Q47772118	Patients' attitudes and experiences of disease-modifying anti-rheumatic drugs in rheumatoid arthritis and spondyloarthritis: A qualitative synthesis.
Q39076719	Patients' considerations in the decision-making process of initiating disease-modifying antirheumatic drugs.
Q40405513	Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists
Q27335007	Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Q35702552	Perceptions of physical activity engagement among adults with rheumatoid arthritis and rheumatologists
Q31104875	Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
Q39702204	Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Q37596119	Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.
Q61446534	Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
Q40502497	Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study.
Q26771652	Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability
Q28077413	Personalized medicine in rheumatology
Q38893192	Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
Q98465864	Pharmacogenetic aspects of methotrexate in a cohort of Colombian patients with rheumatoid arthritis
Q42146734	Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
Q38661046	Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
Q34529981	Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
Q52680975	Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug.
Q37739805	Pharmacotherapy: How well can we compare different biologic agents for RA?
Q47918450	Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Q37628462	Phytomedicine in Joint Disorders
Q54230949	Pneumocystis jiroveci pneumonia in a patient taking Benepali for rheumatoid arthritis.
Q34278716	Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept
Q39656419	Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis
Q30235123	Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies
Q38741139	Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis
Q36981540	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
Q26748614	Posttranslational Modifications and the Immunogenicity of Biotherapeutics
Q27024465	Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
Q38642378	Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.
Q36933286	Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists.
Q61797046	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study
Q87259044	Prediction of radiographic progression in synovitis-positive joints on maximum intensity projection of magnetic resonance imaging in rheumatoid arthritis
Q37118948	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
Q50276961	Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients
Q100464889	Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
Q50674920	Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis.
Q41322125	Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis.
Q38682209	Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study
Q92931974	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment
Q40503217	Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative
Q50024979	Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
Q87339962	Predictors of response to TNF-α antagonist therapy in Chinese rheumatoid arthritis
Q51333035	Predictors of severe radiographic progression in patients with early rheumatoid arthritis: A Prospective observational cohort study.
Q44289433	Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan.
Q87774469	Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort
Q35691806	Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers
Q26824859	Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis
Q47423382	Preventing progression from arthralgia to arthritis: targeting the right patients.
Q38942815	Probiotic bacteria: a viable adjuvant therapy for relieving symptoms of rheumatoid arthritis.
Q40062836	Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database.
Q38745066	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Q37206416	Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target Strategy
Q35728708	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
Q59845151	Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate
Q26786781	Proteomics in Rheumatoid Arthritis Research
Q38210780	Psoriasis: to treat or to manage?
Q26768683	Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes
Q33716790	Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability
Q58093025	Psychometric validation of an empowerment scale for Spanish-speaking patients with rheumatoid arthritis
Q53662070	Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis.
Q90725448	Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
Q90354311	Quality of life in Ecuadorian patients with established rheumatoid arthritis
Q89451139	Qualitätssicherung im diagnostischen und interventionellen rheumatologischen Ultraschall
Q40377000	ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany
Q92464619	Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry
Q30812918	Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial
Q37305945	Rate of Proven Rheumatic Diseases in a Large Collective of Referrals to an Outpatient Rheumatology Clinic Under Routine Conditions
Q36799824	Rational design of antirheumatic prodrugs specific for sites of inflammation
Q59791952	Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
Q58109529	Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study
Q53307697	Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
Q35695760	Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis
Q38594683	Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective
Q37745676	Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis
Q38537504	Recommendations for the management of autoinflammatory diseases.
Q61767472	Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adolopment of the 2015 American College of Rheumatology guidelines
Q37656273	Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor
Q46043250	Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively-treated Patient with Rheumatoid Arthritis
Q28080677	Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
Q88250947	Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial
Q92130819	Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study
Q52869895	Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Q50207072	Relationship between achievement of physical activity goal and characteristics of patients with rheumatoid arthritis
Q35778642	Reliability and Validity of Selected PROMIS Measures in People with Rheumatoid Arthritis
Q42010442	Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor
Q38541414	Remission in rheumatoid arthritis: is it all the same?
Q35578068	Remission of collagen-induced arthritis through combination therapy of microfracture and transplantation of thermogel-encapsulated bone marrow mesenchymal stem cells
Q26738960	Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications
Q48198050	Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis.
Q35807193	Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis'--authors' reply
Q35762424	Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis'.
Q50132991	Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Q48086481	Response to: 'Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study' by Sanmarti et al.
Q52718405	Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment.
Q35744377	Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis
Q30991911	Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry
Q38752119	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis
Q46172380	Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs.
Q47807650	Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Q38847626	Rheumatoid Arthritis Treatment after Methotrexate: Triple Therapy is more Durable than Etanercept
Q96952976	Rheumatoid Arthritis as a Risk Factor for Coronary Artery Calcification and Obstructive Coronary Artery Disease in Patients with Chest Pain: A Registry Based Cross-Sectional Study
Q38287023	Rheumatoid Arthritis, Kartagener's Syndrome, and Hyperprolactinemia: Who Started It?
Q43204160	Rheumatoid arthritis in Latin America. Important challenges to be solved.
Q43795003	Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?
Q36186034	Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study
Q47731218	Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy
Q38357554	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Q36842389	Rheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure - results of the Polish survey in the context of EULAR recommendations
Q26777903	Rheumatoid arthritis treatment: the earlier the better to prevent joint damage
Q36673061	Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis
Q52940652	Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.
Q30244019	Rheumatoid arthritis.
Q45007567	Rheumatoid arthritis: New EULAR guidelines for RA: a job well done
Q55025616	Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.
Q36557985	Rheumatoid polyarthritis suspected in an HIV patient with scleritis, peripheral ulcerative keratitis, and anterior uveitis
Q37086326	Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area
Q57459902	Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: Results from a nationwide KOrean College of Rheumatology BIOlogics (KOBIO) registry
Q41928628	Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.
Q33809045	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
Q35237316	Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.
Q47418727	Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
Q39053105	Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
Q36086443	Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
Q47717769	Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.
Q45908921	Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.
Q38910201	Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis
Q38685009	S100-alarmins: potential therapeutic targets for arthritis
Q39129677	Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan
Q47292924	Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting
Q50318004	Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare
Q38753455	Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis
Q40503152	Safety and efficacy of the leukocytapheresis procedure in eighty-five patients with rheumatoid arthritis
Q41348100	Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Q38176745	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Q55341968	Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan.
Q47755721	Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.
Q34465354	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study
Q39176539	Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Q37063563	Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
Q47870337	Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.
Q26738523	Secukinumab for rheumatology: development and its potential place in therapy
Q48219239	Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
Q40606429	Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory States
Q54966198	Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014.
Q47883430	Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Q57157968	Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis
Q47277890	Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis.
Q51133170	Severe low back pain in patients with rheumatoid arthritis is associated with Disease Activity Score but not with radiological findings on plain X-rays.
Q40116120	Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients
Q51735403	Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial.
Q40062771	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial
Q46426985	Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis
Q39883836	Simultaneous Treatment with Subcutaneous Injection of Golimumab and Intra-articular Injection of Triamcinolone Acetonide (K-Method) in Patients with Rheumatoid Arthritis Undergoing Switching of Biologics: Retrospective Case-Control Study
Q51095051	Single-center, single-dose, open-label, randomized, two-period crossover study on the bioavailability of methotrexate administered using a novel prefilled, needle-free delivery system.
Q34092469	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
Q50079521	Sleep disorders associated with risk of rheumatoid arthritis
Q26852081	Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
Q38988087	Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
Q38242079	Stem cell therapy in autoimmune rheumatic diseases: a comprehensive review
Q55256134	Stevens-Johnsons syndrome or drug-induced lupus - a clinical dilemma: A case report and review of the literature.
Q48241174	Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial
Q38411334	Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis
Q39191675	Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists.
Q90250659	Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
Q55260816	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis.
Q38965691	Survey on management strategies of rheumatoid arthritis in Saudi Arabia: a Saudi Society for Rheumatology Initiative
Q26800154	Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
Q42360803	Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
Q40314992	Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.
Q26749525	Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health
Q30962462	Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic
Q41146155	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Q55064262	Synovial tissue quantitative proteomics analysis reveals paeoniflorin decreases LIFR and ASPN proteins in experimental rheumatoid arthritis.
Q94671452	Synovial tissue transcriptomes of long-standing rheumatoid arthritis are dominated by activated macrophages that reflect microbial stimulation
Q38592344	Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study.
Q37587412	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis
Q41438198	Tamarixinin A Alleviates Joint Destruction of Rheumatoid Arthritis by Blockade of MAPK and NF-κB Activation
Q31017424	Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry
Q30249836	Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
Q39023180	Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice
Q39695085	Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial
Q57911908	Targeted IL-4 therapy synergizes with dexamethasone to induce a state of tolerance by promoting Treg cells and macrophages in mice with arthritis
Q38207142	Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs
Q28073436	Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs
Q40736371	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial
Q46008507	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
Q37635190	Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis
Q64980007	The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.
Q92571224	The Abnormal CD4+T Lymphocyte Subset Distribution and Vbeta Repertoire in New-onset Rheumatoid Arthritis Can Be Modulated by Methotrexate Treament
Q36059239	The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries
Q37208475	The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database
Q33775593	The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
Q26752893	The Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis
Q50109832	The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
Q92662245	The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis
Q37665023	The Reliability of Disease Activity Score in 28 Joints-C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters: A Cross-sectional, Exploratory Study.
Q33665611	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
Q36187856	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank
Q90268330	The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets
Q35622117	The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.
Q48075422	The burden of disease in rheumatoid arthritis
Q26766515	The changing landscape of biosimilars in rheumatology
Q31151686	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights
Q53503464	The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis.
Q35188042	The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review
Q55032091	The course of pain hypersensitivity according to painDETECT in patients with rheumatoid arthritis initiating treatment: results from the prospective FRAME-cohort study.
Q35554857	The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter
Q38222900	The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences
Q47620622	The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab
Q35422834	The efficiency of biologic therapy in a group of patients with rheumatoid arthritis
Q36475622	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression
Q41530781	The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients
Q50916277	The influence of patient perceptions of disease on medication intensification in daily practice.
Q38522457	The optimal combination therapy for the treatment of early rheumatoid arthritis.
Q38436495	The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy
Q34643212	The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network
Q39215645	The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.
Q39341401	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry.
Q47142968	The role of nurse practitioners in delivering rheumatology care and services: Results of a U.S. survey
Q30397234	The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis
Q59503659	The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia
Q28084878	The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
Q39016582	The therapeutic potential of plant flavonoids on rheumatoid arthritis
Q37562571	The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study
Q40942139	The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Q92529275	The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report
Q34597321	The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects
Q26744033	Therapeutic implications of autoantibodies in rheumatoid arthritis
Q38238931	Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides
Q89184171	Therapy: The NICE position on indications for biologics and biosimilars
Q87499001	Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?
Q38267703	Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?
Q47807214	Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort
Q46988765	Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index.
Q45790066	Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.
Q34254377	Time trends in glucocorticoid use in rheumatoid arthritis: results from a population-based inception cohort, 1980-1994 versus 1995-2007.
Q47262286	Timing and impact of decisions to adjust disease-modifying antirheumatic drug therapy for rheumatoid arthritis patients with active disease.
Q37278384	Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials
Q41146132	Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
Q38285827	Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy
Q36968747	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Q37682799	Tocilizumab in the treatment of rheumatoid arthritis and beyond
Q50703895	Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospe
Q54978346	Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Q49901596	Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients
Q42696887	Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study
Q89289045	Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
Q64112990	Top 100 cited articles on rheumatoid arthritis: A bibliometric analysis
Q92200908	Total knee arthroplasty for treatment of rheumatoid arthritis: A protocol for a systematic review of randomized controlled trial
Q40098901	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting
Q52580071	Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis.
Q91283958	Treat-to-target in rheumatoid arthritis - are we there yet?
Q38223570	Treat-to-target in spondyloarthritis: implications for clinical trial designs
Q38476881	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Q64924368	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
Q47131401	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Q41450339	Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs
Q41687116	Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
Q40169531	Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study
Q39815843	Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.
Q36300479	Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations
Q37646610	Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report
Q39372731	Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents
Q57169964	Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis
Q40593579	Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment
Q47132835	Treatment with Biologicals in Rheumatoid Arthritis: An Overview.
Q37340048	Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993-2011.
Q47931220	Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy.
Q53101753	Tubal Pregnancy
Q39449936	Tuberculosis and biologics in rheumatology: India - A special situation.
Q104496434	Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune-mediated inflammatory diseases: A longitudinal population-based analysis using claims data
Q43366110	Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database
Q89684643	Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages
Q50851551	Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
Q35174817	Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial
Q35086227	Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis
Q92608555	Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
Q47693399	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Q52316512	UK-South Asian patients' experiences of and satisfaction toward receiving information about biologics in rheumatoid arthritis.
Q37178957	Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial
Q50092295	Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014).
Q38543383	Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects
Q39174314	Underuse of Methotrexate in the Treatment of Rheumatoid Arthritis: A National Analysis of Prescribing Practices in the US.
Q39178709	Unraveling Patient-Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative Study.
Q38604390	Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib
Q37657244	Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups
Q37622219	Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
Q36932670	Use of Low-Literacy Decision Aid to Enhance Knowledge and Reduce Decisional Conflict Among a Diverse Population of Adults With Rheumatoid Arthritis: Results of a Pilot Study
Q30863740	Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study
Q26783652	Use of biologics in SLE: a review of the evidence from a clinical perspective
Q61811878	Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings
Q36182373	Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population
Q52645897	Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair.
Q57488699	Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol
Q36526969	Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study
Q38648179	Vagal influences in rheumatoid arthritis
Q26827173	Vagus nerve stimulation: a new bioelectronics approach to treat rheumatoid arthritis?
Q39381766	Validation of FLARE-RA, a Self-Administered Tool to Detect Recent or Current Rheumatoid Arthritis Flare
Q53067521	Validation of disease activity indices using the 28 joint counts in systemic sclerosis.
Q31122982	Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria
Q41697121	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients.
Q37282494	Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study
Q89791856	Views on glucocorticoid therapy in rheumatology: the age of convergence
Q55248309	Visceral Leishmaniasis in the Mediterranean area.
Q51104726	Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.
Q39248083	Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study
Q89846223	What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis
Q38211695	When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations
Q36882834	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS).
Q38815746	Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis.
Q62115345	Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis
Q31032743	[Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA].
Q87407703	[Cornerstones of quality assurance in medicine in Germany. Important impulse for the situation in treatment of rheumatism]
Q87844374	[Early undifferentiated arthritis]
Q52849897	[Glucocorticoids].
Q87510841	[Interfaces in outpatient and inpatient rheumatological treatment]
Q56964268	[Long-term glucocorticoid therapy : Is there a safe dosage?]
Q31112566	[Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers].
Q54289165	[Modern disease-modifying antirheumatic drugs].
Q54374459	[New drugs in rheumatology].
Q53566135	[New options for the practice : Update S1/S2 guidelines on rheumatoid arthritis?]
Q85398622	[Pharmacotherapy of psoriatic arthritis. Treatment recommendations against the background of limited evidence]
Q52858056	[Quality of German medical services: a review].
Q36241682	[Rheumatoid arthritis].
Q45950373	[The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].
Q87078574	[Therapeutic strategies for systemic lupus erythematosus]
Q53463643	[Treatment reduction in well-controlled rheumatoid arthritis. State of knowledge].
Q90070474	[Which patients with rheumatoid arthritis do not receive DMARD treatment? Analysis of data from the German Collaborative Arthritis Centers]
Q38751251	bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
Q36098311	cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis.

P6179	Dimensions Publication ID	1001531171
P356	DOI	10.1136/ANNRHEUMDIS-2013-204573
P3181	OpenCitations bibliographic resource ID	39297
P932	PMC publication ID	3933074
P698	PubMed publication ID	24161836
P5875	ResearchGate publication ID	259043515

P50	author	Karel Pavelka	Q12028453
		Maya Hema Buch	Q44940582
		Johannes Jw Bijlsma	Q95966574
		Johanna M. W. Hazes	Q114563672
		Neil Betteridge	Q114775964
		Marios Kouloumas	Q114775965
		Paul Emery	Q19859634
		Maarten Boers	Q29839832
		Gerd-Rüdiger Burmester	Q47261275
		Cécile Gaujoux-Viala	Q47262749
		Marieke Scholte-Voshaar	Q47262767
		Désirée van der Heijde	Q47262835
		Robert Landewé	Q47264015
		Andrea Rubbert-Roth	Q47264821
		Frank Buttgereit	Q47265901
		Maarten de Wit	Q56418351
		Laure Gossec	Q56449280
		Maxime Dougados	Q63136268
		Tore K. Kvien	Q65660760
		Josef S Smolen	Q66753681
		Maurizio Cutolo	Q79075844
		Piet L C M van Riel	Q89845764
		Kevin L Winthrop	Q90243645
		Daniel Aletaha	Q92095812
		Bernard Combe	Q92771497
		Xavier Mariette	Q93104907
		Sofia Ramiro	Q39184066
P2093	author name string	Nemanja Damjanov
		Tuulikki Sokka-Isler
		John B Wong
		David L Scott
		Ferdinand C Breedveld
		Jackie Nam
P2860	cites work	Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study	Q43683228
		COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention	Q43882911
		Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study	Q43914794
		Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial	Q44165611
		Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market	Q44214968
		Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission	Q44383497
		Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice	Q44550260
		Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.	Q44726792
		Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective	Q44782797
		Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study	Q24630541
		Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)	Q24631295
		2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis	Q26828418
		Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis	Q27691388
		Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010	Q27860791
		Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010	Q28111913
		Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components	Q28343376
		The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint	Q28468689
		Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry	Q30645118
		Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.	Q31000488
		Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group	Q33180020
		EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.	Q33292103
		The importance of reporting disease activity states in rheumatoid arthritis clinical trials	Q33365105
		Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations	Q33369384
		Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature	Q33387149
		Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis	Q33389401
		Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment	Q33436856
		Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial	Q33501443
		EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis	Q33505914
		Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion	Q33578743
		Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study	Q44973310
		Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?	Q45235877
		A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study	Q45246613
		Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study	Q45736528
		Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial	Q45842857
		In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis.	Q45900603
		Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial	Q46048883
		Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis	Q46053077
		Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide	Q46173449
		The burden of rheumatoid arthritis and access to treatment: health burden and costs	Q46256192
		The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials	Q46319213
		Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial	Q46778815
		Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial	Q46778819
		The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.	Q51160726
		Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.	Q51168054
		Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard.	Q51760068
		Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.	Q52225534
		Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008.	Q53107015
		American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials	Q57169361
		Clinical evaluation of the efficacy of the P2X7purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine	Q57231903
		Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis	Q58912330
		Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN)	Q60733209
		The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis	Q61912636
		A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial	Q33675468
		Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial	Q33976382
		Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints	Q34033218
		EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs	Q34110066
		Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis	Q34113970
		Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index	Q34210394
		Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study	Q34462435
		Treating rheumatoid arthritis to target: recommendations of an international task force	Q34462557
		Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis	Q34498486
		Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial	Q34552451
		Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study	Q34561675
		Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology	Q34641300
		Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial	Q34651182
		Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.	Q34752154
		Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.	Q35018275
		Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis	Q35084199
		Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology	Q35551818
		Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study	Q35638208
		Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.	Q35669675
		Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial	Q35953319
		Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab	Q35954629
		Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s	Q36550842
		Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study	Q36610390
		Incorporating considerations of resources use into grading recommendations	Q36672034
		New therapies for treatment of rheumatoid arthritis	Q36849874
		Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility	Q36969898
		The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments	Q37044639
		Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster	Q37171211
		A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study	Q37206622
		A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study	Q37206628
		Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research	Q37342445
		Are Glucocorticoids DMARDs?	Q63368183
		Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy	Q69866056
		Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis	Q70821596
		Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis	Q70994774
		Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group	Q73207664
		Validation of rheumatoid arthritis improvement criteria that include simplified joint counts	Q77430935
		Assessing remission in clinical practice	Q79886582
		Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients	Q81377140
		Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade	Q81561216
		The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had	Q82132610
		The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial	Q83223892
		Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study	Q83345167
		A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate	Q83431012
		Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies	Q83455731
		Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial	Q83579024
		Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study	Q83619655
		Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner	Q84131935
		Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis	Q84751886
		Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity	Q84898634
		Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis	Q37395565
		Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors	Q37404890
		Management of RA medications in pregnant patients	Q37511730
		A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis	Q37546519
		The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review	Q37640953
		Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project	Q37715952
		Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis	Q37744195
		Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.	Q37744201
		Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis	Q37744356
		Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis	Q37744366
		Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 compariso	Q37766214
		Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review	Q37808889
		Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action	Q37859226
		Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs	Q37932896
		EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis	Q37950992
		Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis	Q37980421
		The role of biosimilars in the treatment of rheumatic diseases	Q38068691
		Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review	Q38099628
		Proposal for a new nomenclature of disease-modifying antirheumatic drugs	Q38144973
		Discontinuation of biologics in patients with rheumatoid arthritis	Q38152913
		Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis	Q38176549
		Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis	Q38176745
		Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial	Q38498967
		Clinical efficacy of sulphasalazine--a review	Q40931410
		Therapies for active rheumatoid arthritis after methotrexate failure	Q41925478
		A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study	Q41925567
		Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).	Q41929058
		Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial	Q41929303
		Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial	Q41929910
		Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients	Q41933145
		Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients	Q41933182
		Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial	Q41937791
		Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis	Q41945874
		Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthitis.	Q41946962
		EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees	Q41949374
		Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.	Q42683340
		A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study	Q43055381
		Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.	Q43444262
		Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis	Q43463510
		Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study	Q43630815
		Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?	Q43680388
P275	copyright license	Creative Commons Attribution-NonCommercial	Q6936496
P433	issue	3
P407	language of work or name	English	Q1860
P921	main subject	rheumatoid arthritis	Q187255
P304	page(s)	492-509
P577	publication date	2014-03-01
P1433	published in	Annals of the Rheumatic Diseases	Q4767876
P1476	title	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
P478	volume	73

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

scientific article

Reverse relations